Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Carcinoma

Breast Neoplasms

Triple Negative Breast Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total.

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as high staining if they constituted ≥ 10%

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).

Carbonic anhydrase staining levels

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study.

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor

Treatment success in TNBC patients by evaluating changes in CA IX staining levels

Kahramanmaras Sutcu Imam University

Professor, Associate

Respiratory Tract (Lung and Bronchial) Diseases

Digestive System Diseases

Rare Diseases

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

Lung Neoplasms

Carcinoma, Hepatocellular

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Transitional Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Atezolizumab

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.

Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.

Clinical Trials

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)

Hoffmann-La Roche

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma	NCT06309459	Triple Negative... Carbonic Anhydr...	Carbonic anhydr...	18 Years -	Kahramanmaras Sutcu Imam University
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)	NCT03232593	Urothelial Carc... Carcinoma, Non-... Small Cell Lung... Triple Negative... Hepatocellular ...	Atezolizumab	-	Hoffmann-La Roche

Spots Global Cancer Trial Database for triple negative breast carcinoma